Niacin for Cholesterol and Cardiovascular Disease

Nicotinic acid (immediate-release niacin) was the first lipid-modifying drug ever shown to reduce all-cause mortality in a randomized trial — the 1975 Coronary Drug Project, with the benefit persisting at the 15-year follow-up published by Canner in 1986. It remains the most potent HDL-raising agent ever discovered and one of the only readily available drugs that meaningfully lowers lipoprotein(a). Two large negative trials in the 2010s — AIM-HIGH and HPS2-THRIVE — correctly led mainstream cardiology to abandon niacin as an add-on to optimized statin therapy, but they did not invalidate its role as monotherapy in statin-intolerant patients or as a targeted intervention for elevated Lp(a) and ApoB. This page walks the trial history honestly and gives the modern 1-3 g/day immediate-release titration protocol that still has a place in 2026 practice.

Table of Contents

  1. Niacin's Effects on the Lipid Panel
  2. The Coronary Drug Project (1966-1975)
  3. Stockholm Ischaemic Heart Disease Study (1988)
  4. AIM-HIGH (2011)
  5. HPS2-THRIVE (2014)
  6. Why the Modern Trials Were Negative
  7. Modern Positioning — When Niacin Still Makes Sense
  8. The Lipoprotein(a) Question
  9. Mechanism of Lipid Modification
  10. 1-3 g/day Immediate-Release Titration Protocol
  11. Cautions
  12. Key Research Papers
  13. Connections

Niacin's Effects on the Lipid Panel

At pharmacological doses of immediate-release nicotinic acid (1000-3000 mg/day), no single agent matches niacin's spectrum of lipid effects:

Lipid Marker Niacin Effect (1-3 g/day IR) Comparable Agents
HDL cholesterol+15 to +35%No drug matches this
LDL cholesterol−5 to −25%Statins (much stronger); ezetimibe; PCSK9 inhibitors
Triglycerides−20 to −50%Fibrates; high-dose omega-3 (icosapent ethyl)
Lipoprotein(a) [Lp(a)]−20 to −30%PCSK9 inhibitors (similar); pelacarsen (investigational); apheresis
ApoB−15 to −25%Statins; ezetimibe; PCSK9 inhibitors
LDL particle patternShifts small-dense to large-buoyant (less atherogenic)Fibrates (similar)

The HDL-raising and Lp(a)-lowering effects are essentially unique to niacin among broadly available drugs. PCSK9 inhibitors (alirocumab, evolocumab) lower Lp(a) by similar magnitudes but cost $5000-7000/year — thousands of times more than niacin. The Lp(a) effect, in particular, makes niacin clinically interesting in 2026 because elevated Lp(a) is an underrecognized cardiovascular risk factor with limited therapeutic options.

For the broader picture of niacin's lipid effects in our existing literature, see Niacin & Cholesterol (the long-form article) and Cholesterol Management.

Back to Table of Contents

The Coronary Drug Project (1966-1975)

The Coronary Drug Project (CDP) was a landmark National Heart, Lung, and Blood Institute trial of secondary prevention in 8341 men aged 30-64 who had survived at least one myocardial infarction. Participants were randomized to one of five lipid-modifying interventions or placebo and followed for 5-8.5 years.

The five treatment arms

  1. Niacin (immediate-release nicotinic acid, 3000 mg/day) — 1119 patients
  2. Clofibrate (1800 mg/day)
  3. Two estrogen doses (both discontinued early for safety)
  4. Dextrothyroxine (discontinued early for cardiovascular harm)
  5. Placebo — 2789 patients

The CDP 1975 publication (JAMA)

The Canner 1986 follow-up (JACC) — the mortality benefit emerges

Paul Canner reanalyzed the CDP cohort 15 years after the trial began — 9 years after active treatment had ended. The result is one of the most striking long-term follow-up findings in cardiovascular medicine:

The CDP/Canner result remained the dominant cardiovascular evidence for niacin for the next 25 years, supporting widespread clinical use of niacin (often combined with bile-acid sequestrants and later with low-dose statins) for cardiovascular prevention.

Back to Table of Contents

Stockholm Ischaemic Heart Disease Study (1988)

Lars Carlson and Goran Rosenhamer published the Stockholm Ischaemic Heart Disease Secondary Prevention Study in Acta Medica Scandinavica in 1988. 555 post-MI patients were randomized to standard care or to combination nicotinic acid (3000 mg/day) plus clofibrate (2000 mg/day), and followed for 5 years.

The Stockholm study was a second positive RCT in the pre-statin era, reinforcing the CDP findings. Notably, both the CDP and the Stockholm trials used immediate-release nicotinic acid at gram-range doses — not extended-release formulations.

Back to Table of Contents

AIM-HIGH (2011)

AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) randomized 3414 patients with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia (low HDL, high triglycerides) to:

The trial was stopped early at 3 years for futility. Published in NEJM 2011:

The trial had design limitations — small placebo dose of niacin (50 mg) was given to mask the flush, which may have created lipid effects in the "placebo" group; the population had already achieved aggressive LDL lowering on statin before randomization, leaving little room for incremental benefit; and the trial was underpowered after early stopping.

Back to Table of Contents

HPS2-THRIVE (2014)

HPS2-THRIVE (Heart Protection Study 2 — Treatment of HDL to Reduce the Incidence of Vascular Events) was the larger trial that effectively ended mainstream cardiology's use of niacin. 25,673 patients with vascular disease already taking effective LDL-lowering therapy (mostly simvastatin 40 mg) were randomized to:

Median follow-up was 3.9 years. Published in NEJM 2014:

HPS2-THRIVE was definitive that extended-release niacin plus laropiprant adds harm without benefit when given on top of optimized statin therapy. Merck withdrew the niacin/laropiprant combination (Tredaptive/Cordaptive) from market globally. The FDA pulled approval for niacin add-on to statins (Advicor and Simcor combination products were withdrawn in 2016).

Back to Table of Contents

Why the Modern Trials Were Negative

The collapse of niacin as add-on to statins did not invalidate the earlier evidence. Several factors explain the divergence:

  1. Background statin therapy was the difference. CDP (1975) was conducted before statins existed — placebo patients had LDL of ~130-140 mg/dL on average. AIM-HIGH and HPS2-THRIVE patients had LDL already aggressively lowered to ~70 mg/dL by statin therapy. The marginal benefit of additional HDL-raising or further LDL-lowering at these already-low levels appears minimal.
  2. The "HDL hypothesis" itself was wrong. Mendelian randomization studies (CETP variants and others) have shown that genetically determined HDL levels do not causally protect against CHD. HDL is a marker of cardiometabolic health, not a causal protective particle. Drugs that raise HDL (CETP inhibitors like dalcetrapib, evacetrapib, anacetrapib; niacin) have failed to translate HDL gains into outcomes.
  3. Laropiprant added cardiovascular harm. The flush-blocking adjunct used in HPS2-THRIVE was implicated in some of the excess adverse events — HPS2-THRIVE was not a pure test of niacin alone.
  4. Extended-release vs immediate-release. Both modern trials used ER-niacin. The historical positive trials (CDP, Stockholm) used IR-niacin at higher peak concentrations. Whether IR vs ER pharmacokinetics matter for outcomes is an unresolved question.
  5. LDL particle composition matters more than LDL concentration. Niacin's benefit may operate primarily through ApoB and Lp(a) reduction and LDL-particle-size shift, which are not directly captured by standard lipid panels.

The honest reading of the totality of evidence: niacin works when it is the primary lipid-modifying agent in patients who would otherwise have untreated dyslipidemia; it does not add incremental benefit when stacked on top of optimized statin therapy.

Back to Table of Contents

Modern Positioning — When Niacin Still Makes Sense

In 2026 cardiology practice, niacin's legitimate clinical niches are narrower than they were in 1995 but remain real:

For the broader cardiovascular workup, see Cardiovascular Disease and Lipid Panel.

Back to Table of Contents

The Lipoprotein(a) Question

Lipoprotein(a) is an LDL-like particle with an additional apolipoprotein(a) covalently bound. Lp(a) levels are 80-90% genetically determined — you inherit your Lp(a) at birth and it changes little over a lifetime. Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) is an independent risk factor for atherosclerotic cardiovascular disease and aortic stenosis, with the relative risk roughly equivalent to elevated LDL.

The problem: until recently, almost no drug meaningfully lowered Lp(a):

For a patient with Lp(a) of 100 mg/dL and otherwise well-controlled lipids, niacin remains a defensible option pending the pelacarsen outcomes data. The Lp(a)-lowering effect is one of niacin's most enduring claims to clinical relevance.

Back to Table of Contents

Mechanism of Lipid Modification

Niacin's lipid-modifying effects derive from multiple convergent mechanisms:

The flush is a side effect of GPR109A activation on Langerhans cells in the skin, where it triggers prostaglandin D2 release and consequent vasodilation. This is separate from the adipose GPR109A effect that drives lipid modification — you cannot block the flush without partially blocking the lipid benefit (which is why laropiprant failed in HPS2-THRIVE).

Back to Table of Contents

1-3 g/day Immediate-Release Titration Protocol

For appropriately selected patients (see Modern Positioning above), the practical protocol is:

Pre-treatment workup

Titration schedule

  1. Weeks 1-2: 100 mg IR nicotinic acid with the largest meal of the day. Optional aspirin 325 mg 30 minutes before the dose during the first 1-2 weeks to attenuate flushing.
  2. Weeks 3-4: Increase to 250 mg with the largest meal (or 100 mg twice daily). Reassess flush tolerance.
  3. Weeks 5-6: 500 mg once daily with the largest meal, or 250 mg twice daily.
  4. Weeks 7-8: 500 mg twice daily (1 g/day total).
  5. Weeks 9-12: Titrate further toward 1500-2000 mg/day in 2-3 divided doses with meals if needed to reach lipid targets.
  6. Maintenance: 1000-2000 mg/day in divided doses for most patients; up to 3000 mg/day in selected cases with rigorous monitoring.

Monitoring schedule

Critical formulation choice

Use immediate-release (IR) nicotinic acid only. Brand-name preparations have largely disappeared from the US market; quality generic IR niacin is widely available from reputable supplement manufacturers. Sustained-release (SR) and extended-release (ER) formulations — despite causing less flush — carry substantially higher hepatotoxicity risk and should NOT be used at gram-range doses. The McKenney 1994 JAMA paper directly compared and found dramatic SR-niacin hepatotoxicity at lipid-modifying doses.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Coronary Drug Project Research Group (1975). Clofibrate and niacin in coronary heart disease. JAMA. — PubMed
  2. Canner PL et al. (1986). Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JACC. — PubMed
  3. Carlson LA, Rosenhamer G (1988). Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. — PubMed
  4. AIM-HIGH Investigators / Boden WE et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEJM. — PubMed
  5. HPS2-THRIVE Collaborative Group (2014). Effects of extended-release niacin with laropiprant in high-risk patients. NEJM. — PubMed
  6. Carlson LA (2005). Nicotinic acid: the broad-spectrum lipid drug — a 50th anniversary review. J Intern Med. — PubMed
  7. Bruckert E et al. (2010). Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. — PubMed
  8. McKenney JM et al. (1994). A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. — PubMed
  9. Niacin and Lp(a) reduction — PubMed
  10. Niacin and ApoB lowering — PubMed
  11. GPR109A receptor and niacin lipid mechanism — PubMed
  12. Niacin in statin-intolerant patients — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents